(Q44657551)

5 December 2017

title

Current status of lipid management of hypertensive patients (English)

1 reference

5 December 2017

Current Status of Lipid Management of Hypertensive Patients (English)

1 reference

https://api.crossref.org/works/10.1291/HYPRES.26.699

Cardiology and cardiovascular medicine

2 April 2024

main subject

1 reference

https://api.crossref.org/works/10.1291/HYPRES.26.699

2 April 2024

1 reference

https://api.crossref.org/works/10.1291/HYPRES.26.699

2 April 2024

1 reference

https://api.crossref.org/works/10.1291/HYPRES.26.699

2 April 2024

author name string

Koichi Matsubara

1

1 reference

5 December 2017

Yasutaka Yamamoto

2

1 reference

5 December 2017

Kazuhiko Sonoyama

3

1 reference

5 December 2017

Go Igawa

4

1 reference

5 December 2017

Masako Furuse

5

1 reference

5 December 2017

Toru Yatsuhashi

6

1 reference

5 December 2017

Toshihiro Hamada

7

1 reference

5 December 2017

Kazuhide Ogino

8

1 reference

5 December 2017

Osamu Igawa

9

1 reference

5 December 2017

Ichiro Hisatome

10

1 reference

5 December 2017

Chiaki Shigemasa

11

1 reference

5 December 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14620924

2 April 2024

publication date

1 September 2003

1 reference

full work available at URL

5 December 2017

https://www.jstage.jst.go.jp/article/hypres/26/9/26_9_699/_pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14620924

2 April 2024

published in

Hypertension Research

1 reference

5 December 2017

volume

26

1 reference

5 December 2017

issue

9

1 reference

5 December 2017

page(s)

699-704

1 reference

Guidelines for the management of hypertension for general practitioners

5 December 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1291/HYPRES.26.699

Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study

2 April 2024

2

1 reference

https://api.crossref.org/works/10.1291/HYPRES.26.699

Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study.

2 April 2024

3

1 reference

https://api.crossref.org/works/10.1291/HYPRES.26.699

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

2 April 2024

6

1 reference

https://api.crossref.org/works/10.1291/HYPRES.26.699

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

2 April 2024

8

1 reference

https://api.crossref.org/works/10.1291/HYPRES.26.699

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

2 April 2024

9

1 reference

https://api.crossref.org/works/10.1291/HYPRES.26.699

Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.

2 April 2024

10

1 reference

https://api.crossref.org/works/10.1291/HYPRES.26.699

Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel

2 April 2024

11

1 reference

https://api.crossref.org/works/10.1291/HYPRES.26.699

National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

2 April 2024

12

1 reference

https://api.crossref.org/works/10.1291/HYPRES.26.699

Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension

2 April 2024

13

1 reference

https://api.crossref.org/works/10.1291/HYPRES.26.699

Report of the Japan Atherosclerosis Society (JAS) Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese adults

2 April 2024

14

1 reference

https://api.crossref.org/works/10.1291/HYPRES.26.699

Pravastatin use and risk of coronary events and cerebral infarction in japanese men with moderate hypercholesterolemia: the Kyushu Lipid Intervention Study

2 April 2024

15

1 reference

https://api.crossref.org/works/10.1291/HYPRES.26.699

A comparison of low versus standard dose pravastatin therapy for the prevention of cardiovascular events in the elderly: the pravastatin anti-atherosclerosis trial in the elderly (PATE).

2 April 2024

16

1 reference

https://api.crossref.org/works/10.1291/HYPRES.26.699

2 April 2024

17

59 (Suppl 3)

462

Itakura H

2001

1 reference

https://api.crossref.org/works/10.1291/HYPRES.26.699

The status of hypertension management in Japan in 2000.

2 April 2024

18

1 reference

https://api.crossref.org/works/10.1291/HYPRES.26.699

Interactions between hypercholesterolemia and hypertension: implications for therapy

2 April 2024

19

1 reference

https://api.crossref.org/works/10.1291/HYPRES.26.699

Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia

2 April 2024

20

1 reference

https://api.crossref.org/works/10.1291/HYPRES.26.699

Are we mortgaging the medical profession?

2 April 2024

21

1 reference

https://api.crossref.org/works/10.1291/HYPRES.26.699

Pravastatin attenuates cardiovascular inflammatory and proliferative changes in a rat model of chronic inhibition of nitric oxide synthesis by its cholesterol-lowering independent actions

2 April 2024

22

1 reference

https://api.crossref.org/works/10.1291/HYPRES.26.699

Direct effects of statins on cells primarily involved in atherosclerosis

2 April 2024

23

1 reference

https://api.crossref.org/works/10.1291/HYPRES.26.699

Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia

2 April 2024

24

1 reference

https://api.crossref.org/works/10.1291/HYPRES.26.699

Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy

2 April 2024

25

1 reference

https://api.crossref.org/works/10.1291/HYPRES.26.699

Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias

2 April 2024

26

1 reference

https://api.crossref.org/works/10.1291/HYPRES.26.699

Clinically relevant differences between the statins: implications for therapeutic selection

2 April 2024

27

1 reference

https://api.crossref.org/works/10.1291/HYPRES.26.699

Regulation of apo A-I gene expression by fibrates

2 April 2024

28

1 reference

https://api.crossref.org/works/10.1291/HYPRES.26.699

A community-wide survey of physician practices and attitudes toward cholesterol management in patients with recent acute myocardial infarction

2 April 2024

29

1 reference

https://api.crossref.org/works/10.1291/HYPRES.26.699

Usefulness of cardiovascular family history data for population-based preventive medicine and medical research (the Health Family Tree Study and the NHLBI Family Heart Study).

2 April 2024

30

1 reference

https://api.crossref.org/works/10.1291/HYPRES.26.699

A prospective study of parental history of myocardial infarction and coronary artery disease in men.

2 April 2024

32

1 reference

https://api.crossref.org/works/10.1291/HYPRES.26.699

2 April 2024

Identifiers

1 reference

Dimensions Publication ID

5 December 2017

1001043117

0 references

1 reference